Indeed, the cross reaction of glucagon at the GLP-1R has proven to be vital for pancreas function and dual (or triple) agonists of the GCGR and GLP-1R (and GIP receptor) are currently being studied for the treatment of metabolic disorders. Here, GLP1R is linked to metabolic disease.